CPNE1 was a target of miR-335–5 and CPNE1 silencing could effectively improve clinical responses of EGFR-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer [49]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.